Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Shortening the drug discovery pipeline: small molecule high content screening for lead discovery in neglected disease

There is a pressing, global need for new therapies for neglected diseases such as Tuberculosis, Leishmaniasis and Chagas. Traditional lead discovery approaches, while effective have not been widely applied to neglected diseases as they are expensive and time consuming. At Institut Pasteur Korea, we have developed a core technology that enables the high content screening of hundreds of thousands of small molecules against the disease of interest. In doing so, we utilize relevant disease models that allow us to interrogate the disease in the context of the cell and the host-pathogen factors required for invasion, replication, persistence and release. The application of this core technology against Tuberculosis, Leishmaniasis and Chagas disease has resulted in the identification of novel, active compounds in less time and at less cost than traditional drug discovery methods. As these active compounds were identified in a cellular context, they can provide a more relevant starting point for new therapies.

Author information

Correspondence to Jonathan Cechetto.

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Cechetto, J., Jeon, H.K., Jang, J. et al. Shortening the drug discovery pipeline: small molecule high content screening for lead discovery in neglected disease. BMC Proc 5, P38 (2011). https://doi.org/10.1186/1753-6561-5-S1-P38

Download citation

Keywords

  • Tuberculosis
  • Small Molecule
  • Active Compound
  • Drug Discovery
  • Leishmaniasis